AI for protein design.
Pushing the limits.

Scroll Down

About us

From discovery to design.

We design it from day one, revolutionizing how protein therapeutics are developed.

At Galux, we develop a pioneering protein therapeutics design platform, GaluxDesign, that uniquely integrates
artificial intelligence and physical principles.

We bring your imagined proteins to life.

Our platform

GaluxDesign: Integrating physics into AI

Our proprietary AI platform is trained to design proteins from first principles,
resulting in its modality-agnostic nature.

Its unprecedented accuracy has been demonstrated through the de novo design
of antibodies, one of the most challenging protein classes to design.

Latest stories from Galux

Galux: Scaling AI-designed biologics
Read More
AI meets antibody design: Galux draws $29M series B for drug R&D
Read More
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery
Read More
ISU Abxis and Galux Launch AI-Driven Collaboration to Develop Next-Generation Therapies for Rare Diseases
Read More
For its next AI deal, Boehringer turns to Galux for precision protein design
Read More
Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design
Read More

Join forces with Galux
to lead the next wave of drug innovation.
Together, we push boundaries
and redefine what's possible in medicine.

image